- Home
- BIVI vs LUCD Comparison
BIVI vs LUCD Comparison
Compare BIVI & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- LUCD
- Stock Information
- Founded
- BIVI 2013
- LUCD 2018
- Country
- BIVI United States
- LUCD United States
- Employees
- BIVI N/A
- LUCD N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BIVI Health Care
- LUCD Health Care
- Exchange
- BIVI Nasdaq
- LUCD Nasdaq
- Market Cap
- BIVI 49.8M
- LUCD 51.6M
- IPO Year
- BIVI N/A
- LUCD 2021
- Fundamental
- Price
- BIVI $1.48
- LUCD $1.46
- Analyst Decision
- BIVI Strong Buy
- LUCD Strong Buy
- Analyst Count
- BIVI 1
- LUCD 4
- Target Price
- BIVI $30.00
- LUCD $3.63
- AVG Volume (30 Days)
- BIVI 596.3K
- LUCD 680.2K
- Earning Date
- BIVI 02-11-2025
- LUCD 03-24-2025
- Dividend Yield
- BIVI N/A
- LUCD N/A
- EPS Growth
- BIVI N/A
- LUCD N/A
- EPS
- BIVI N/A
- LUCD N/A
- Revenue
- BIVI N/A
- LUCD $4,189,000.00
- Revenue This Year
- BIVI N/A
- LUCD $91.72
- Revenue Next Year
- BIVI N/A
- LUCD $139.38
- P/E Ratio
- BIVI N/A
- LUCD N/A
- Revenue Growth
- BIVI N/A
- LUCD 179.27
- 52 Week Low
- BIVI $1.04
- LUCD $0.63
- 52 Week High
- BIVI $33.10
- LUCD $1.63
- Technical
- Relative Strength Index (RSI)
- BIVI 32.72
- LUCD 73.16
- Support Level
- BIVI $1.45
- LUCD $1.34
- Resistance Level
- BIVI $1.88
- LUCD $1.63
- Average True Range (ATR)
- BIVI 0.16
- LUCD 0.14
- MACD
- BIVI -0.01
- LUCD 0.04
- Stochastic Oscillator
- BIVI 5.08
- LUCD 76.87
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.